Spire Healthcare turns down acquisition proposal from Mediclinic

Date: 2017-10-24   Author: Saipriya Iyer  Category: #news

Spire Healthcare turns down acquisition proposal from Mediclinic

In what may be touted as an unforeseen rejection of sorts, acclaimed UK-based medical care firm, Spire Healthcare Group, has spurned a takeover proposition from its largest shareholder - Mediclinic International. If reports are to be believed, the representatives of the country’s second largest provider of private healthcare state that the proposed deal was offered for a valuation that “significantly undervalues Spire and its prospects”.

For the record, Mediclinic, based in South Africa, owns more than 30% of stake in Spire Healthcare, making the firm one of the most pivotal shareholders of the UK-based company. Mediclinic’s investments in Spire commenced back in 2015, when the company’s top shots recognized the need to tap into the robustly expanding private healthcare service domain. Experts cite that acquiring Spire would prove to be rewarding for the Stellenbosch-headquartered behemoth, which has been carousing through a series of profitable acquisitions since a while now, across Europe, Africa, and Middle East, under the tutelage of Mediclinic’s current CEO, Danie Meintjes.

Plausibly in a bid to conduct its fourth transaction for 2017, Mediclinic approached Spire with an offer of around GBP 1.2 billion (USD 1.6 billion). Reportedly, the offer valued Spire’s shares at 298.6 pence apiece in cash and stock. Sources claim that this represents a 29% premium to the private hospital operator’s closing price prior to the day the offer was made, perhaps on the grounds of which the rejection stands currently.

Analysts cite that Spire’s rejection may have also additionally stemmed from the fact that Mediclinic is still attempting to digest the UAE-based Al Noor Hospital assets it acquired in a reverse takeover about two years ago, and perhaps, currently lacks the competence for another major acquisition.

Spire’s shares have had an arduous run so far in 2017. The company’s shares fell nearly by 40% from 361 pence in July, as the profits from the first two quarters dropped by almost 75% on the grounds of lawsuit settlements. Quite surprisingly though, post Spire’s rejection of Mediclinic’s takeover bid, the shares of the UK-based private hospital operator jumped 12% in the morning trading.



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Leaded Disc MOV Market 2021-2027 Detailed Analysis and Growth Strategies, Regional and Recent Scenario Analysis

Author: Sachin Pashte

Decoding Covid-19 impact on Leaded Disc MOV market over 2021-2027, with report inclusions as growth determinants, challenges, and revenue generating prospects.

The recent study on Leaded Disc MOV market is compiled with an objective to a...


Plastic Pre-Filled Syringes Sales Market Share, Growth, Statistics, by Application, Production, Revenue & Forecast to 2027

Author: Sachin Pashte

Market Study Report adds a new research on Global Plastic Pre-Filled Syringes Sales Market for the period of 2021-2027 that shows the growth of the market is rising at a Steady CAGR to 2027.

The recent study on Plastic Pre-Filled Syringe...


Clindamycin Phosphate and Benzoyl Peroxide Sales market to showcase strong CAGR between 2027 and 2027

Author: Sachin Pashte

Primary aspects discussed in Clindamycin Phosphate and Benzoyl Peroxide Sales market research report: profit margins, pricing models, production and consumption volume, demand and supply trends, COVID-19 impact.

The recent study on Clind...